Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor.
Inoue
T
T
Shima
M
M
Takeyama
M
M
Matsumoto
T
T
Nishiya
K
K
Tanaka
I
I
Sakurai
Y
Y
Giddings
J C
JC
Yoshioka
A
A
D000293:Adolescent; D005169:Factor VIII / Q000502:physiology* / Q000627:therapeutic use; D006406:Hematoma / Q000517:prevention & control; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007167:Immunotherapy / Q000379:methods; D008297:Male; D016896:Treatment Outcome; D014841:von Willebrand Factor / Q000627:therapeutic use*
D014841:von Willebrand Factor; C078147:F8 protein, human; D005169:Factor VIII